Business Context and Reporting Period
Company: Mustang Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 16, 2024
Reporting Period: Events occurring on May 16, 2024, regarding Nasdaq listing compliance.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for these metrics.
Material Changes and Listing Status
- Minimum Bid Price Deficiency: On May 16, 2024, the Company received a "Second Letter" from Nasdaq stating its common stock closed below $1.00 per share for 31 consecutive business days, violating Listing Rule 5550(a)(2).
- Grace Period: The Company has a 180-calendar day grace period ending November 12, 2024, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
- Stockholders' Equity Deficiency: The Company previously received a "First Letter" (March 13, 2024) regarding non-compliance with the $2.5 million minimum stockholders' equity requirement (Rule 5550(b)(1)).
- Extension Granted: On May 16, 2024, Nasdaq granted an extension until September 9, 2024, for the Company to regain compliance with the stockholders' equity requirement.
Outlook, Risks, and Management Commentary
Management Intent: The Company intends to monitor the closing bid price and consider all available options to remedy deficiencies, including a potential reverse stock split, though no decision has been made. The Company plans to take reasonable measures to regain compliance with all listing rules.
Risks and Contingencies:
- There is no assurance the Company will successfully maintain its Nasdaq listing.
- If compliance is not achieved by November 12, 2024, the Company may be eligible for a second 180-day period only if it meets initial listing criteria and provides notice of a reverse stock split.
- Failure to regain compliance could result in delisting.
- Forward-looking statements are subject to risks including the development stage of product candidates, financing needs, and clinical trial uncertainties.
Investor Verification Checklist
- Verify the current closing bid price of MBIO stock to assess progress toward the $1.00 threshold.
- Review the Company's most recent 10-Q or 10-K to determine current stockholders' equity levels relative to the $2.5 million requirement.
- Monitor future announcements regarding the potential implementation of a reverse stock split.
- Check for any subsequent correspondence from Nasdaq regarding the status of the compliance plans.